JP2022509221A5 - - Google Patents

Info

Publication number
JP2022509221A5
JP2022509221A5 JP2021530081A JP2021530081A JP2022509221A5 JP 2022509221 A5 JP2022509221 A5 JP 2022509221A5 JP 2021530081 A JP2021530081 A JP 2021530081A JP 2021530081 A JP2021530081 A JP 2021530081A JP 2022509221 A5 JP2022509221 A5 JP 2022509221A5
Authority
JP
Japan
Prior art keywords
hpv
composition according
human papillomavirus
proteins
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021530081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509221A (ja
JP7688576B6 (ja
JP7688576B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063172 external-priority patent/WO2020112720A1/en
Publication of JP2022509221A publication Critical patent/JP2022509221A/ja
Publication of JP2022509221A5 publication Critical patent/JP2022509221A5/ja
Priority to JP2024213945A priority Critical patent/JP2025060647A/ja
Application granted granted Critical
Publication of JP7688576B2 publication Critical patent/JP7688576B2/ja
Publication of JP7688576B6 publication Critical patent/JP7688576B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530081A 2018-11-28 2019-11-26 共生ウイルスに対するｔ細胞指向性抗がんワクチン Active JP7688576B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213945A JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862772443P 2018-11-28 2018-11-28
US62/772,443 2018-11-28
US201962831691P 2019-04-09 2019-04-09
US62/831,691 2019-04-09
US201962909698P 2019-10-02 2019-10-02
US62/909,698 2019-10-02
PCT/US2019/063172 WO2020112720A1 (en) 2018-11-28 2019-11-26 T cell-directed anti-cancer vaccines against commensal viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213945A Division JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Publications (4)

Publication Number Publication Date
JP2022509221A JP2022509221A (ja) 2022-01-20
JP2022509221A5 true JP2022509221A5 (enExample) 2022-11-10
JP7688576B2 JP7688576B2 (ja) 2025-06-04
JP7688576B6 JP7688576B6 (ja) 2025-07-04

Family

ID=70853016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530081A Active JP7688576B6 (ja) 2018-11-28 2019-11-26 共生ウイルスに対するｔ細胞指向性抗がんワクチン
JP2024213945A Pending JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213945A Pending JP2025060647A (ja) 2018-11-28 2024-12-06 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Country Status (5)

Country Link
US (1) US20220001004A1 (enExample)
EP (1) EP3886886A4 (enExample)
JP (2) JP7688576B6 (enExample)
CN (1) CN113347987A (enExample)
WO (1) WO2020112720A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗
EP4281106A4 (en) * 2021-01-21 2024-12-25 The General Hospital Corporation T-CELL-TARGETED ANTICANCER VACCINES AGAINST COMMENSAL VIRUSES FOR THE TREATMENT OF MUCOSAIC CARCINOMAS
US20230178197A1 (en) * 2021-12-03 2023-06-08 nference, inc. Techniques for predicting immunosuppression status
CN117982638B (zh) * 2024-02-04 2024-11-01 上海安奕康生物科技有限公司 免疫佐剂联合pd-1抗体药物在治疗胰腺癌中的应用
WO2025212374A1 (en) * 2024-04-02 2025-10-09 The General Hospital Corporation Methods for utilizing commensal polyomavirus for cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132201A0 (en) * 1997-04-08 2001-03-19 Merck & Co Inc Stabilized human papillomavirus formulations
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP6035503B2 (ja) * 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
EA019836B1 (ru) * 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
US9717783B2 (en) * 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗

Similar Documents

Publication Publication Date Title
JP2025060647A5 (enExample)
Bridle et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
JP2014534202A5 (enExample)
US8728485B2 (en) Peptide library obtained from multi-clade chimeric immunogens derived from highly conserved regions of the human immunodeficiency virus type 1 (HIV-1) consensus proteome
HRP20251176T1 (hr) Cjepivo za uporabu u profilaksi i/ili liječenju bolesti
JP2023513720A5 (enExample)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2009544614A5 (enExample)
RU2015155821A (ru) Вакцины против малярии
Jiang et al. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy
JP2021520818A5 (enExample)
JP2016074727A5 (enExample)
Alderson et al. Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
AU2022205163A1 (en) Hepatitis B immunisation regimen and compositions
BR112020012361A2 (pt) constructos de antígeno do vírus epstein-barr
JP2022539157A5 (enExample)
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
RU2015115785A (ru) Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака
JP2010523138A5 (enExample)
Song et al. A synthetic SARS-CoV-2-derived T-cell and B-cell peptide cocktail elicits full protection against lethal Omicron BA. 1 infection in H11-K18-hACE2 mice
Panahi et al. Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses
JP2013512866A5 (enExample)
WO2019100147A1 (en) Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
JP2002510496A (ja) 細胞傷害性ｔ細胞を誘導するための医薬
EP3432923B1 (en) Hcv vaccines